

**Clinical trial results:****A phase II trial of the addition of ipilumimab to carboplatin and etoposide chemotherapy for the first line treatment of extensive small cell lung cancer****Summary**

EudraCT number	2010-021863-34
Trial protocol	GB
Global end of trial date	29 May 2014

Results information

Result version number	v1 (current)
This version publication date	29 December 2021
First version publication date	29 December 2021
Summary attachment (see zip file)	Trial Publication (1-s2.0-S1556086416305032-main.pdf)

Trial information**Trial identification**

Sponsor protocol code	RHMCAN0739
-----------------------	------------

Additional study identifiers

ISRCTN number	ISRCTN14095893
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Southampton University Hospitals NHS Trust
Sponsor organisation address	Tremona Road, SOUTHAMPTON, United Kingdom, SO16 6YD
Public contact	Edurne Arriola, MD, PhD, Southampton NIHR Experimental Cancer Medicine Centre, Tremona Road, Southam, Edurne Arriola, MD, PhD, Southampton NIHR Experimental Cancer Medicine Centre, Tremona Road, Southam, 44 2380595000, e.arriola-aperribay@soton.ac.uk
Scientific contact	Edurne Arriola, MD, PhD, Southampton NIHR Experimental Cancer Medicine Centre, Tremona Road, Southam, Edurne Arriola, MD, PhD, Southampton NIHR Experimental Cancer Medicine Centre, Tremona Road, Southam, 44 2380595000, e.arriola-aperribay@soton.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 May 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 May 2014
Global end of trial reached?	Yes
Global end of trial date	29 May 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The trial aims to answer whether the addition of Ipilimumab to carboplatin and etoposide chemotherapy for patients with extensive stage small cell lung cancer is able to improve outcome for these patients as assessed by the proportion of patients alive and without progression at 1 year.

Protection of trial subjects:

1.3.4 Clinical safety with Ipilimumab

Ipilimumab immunotherapy is currently under investigation in patients with unresectable advanced melanoma (unresectable Stage III or Stage IV) to potentially demonstrate an improvement on a large unmet medical need in this population.

Ipilimumab has been administered to approximately 2901 patients with different cancers in 25 completed or ongoing clinical trials as of 31-Mar-2009 with a dose range between 0.3 mg/kg and 20 mg/kg and in various combinations.

In general, the safety profile of Ipilimumab administered as single doses of up to 20 mg/kg and multiple doses of up to 10 mg/kg every 3 weeks was characterized by adverse reactions that were mostly immune in nature. Drug-related SAEs were reported in studies of Ipilimumab administered as monotherapy, as well as in combination with vaccines, cytokines, Chemotherapy, or radiation therapy. The overall summary of safety for the 2901 patients treated with Ipilimumab in the completed or ongoing clinical trials and the subset of 658 patients treated at the 10 mg/kg dose level is presented in Table 1.

Table 1: Ipilimumab - Overall Summary of Safety

Number of Patients (%)		
Ipilimumab 0.3 - 20 mg/kg		
N = 2901	Ipilimumab 10 mg/kg	
N = 658		
Any Drug-related AE	2357 (81.2)	561 (85.3)
Grade 1	699 (24.1)	158 (24.0)
Grade 2	889 (30.6)	198 (30.1)
Grade 3	617 (21.3)	163 (24.8)
Grade 4	127 (4.4)	38 (5.8)
Grade 5	20 (0.7)	4 (0.6)
Any Serious Adverse Events	1258 (43.4)	310 (47.1)
Grade 3 - 4	806 (27.8)	179 (27.2)
Any Drug-related Serious Adverse Events	595 (20.5)	179 (27.2)
Grade 3 - 4	469 (16.2)	140 (21.3)

Complete information on the clinical safety with Ipilimumab can be found in the current Ipilimumab Investigator Brochure (IB).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 June 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 42
Worldwide total number of subjects	42
EEA total number of subjects	42

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	32
From 65 to 84 years	10
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 42 patients were enrolled between September 2011 and April 2014; 39 were evaluable for safety and 38 for efficacy

Pre-assignment

Screening details:

The patients were men and women aged 18 and older who had a histological or cytological diagnosis of SCLC; no previous systemic therapy for SCLC; an Eastern Cooperative Oncology Group performance status of 0 or 1; adequate baseline laboratory test results; and no active or chronic infection with human immunodeficiency virus, hepatitis B, or hepatitis C

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	Combination therapy
Arm description: -	
Arm type	Single
Investigational medicinal product name	IPILUMUMAB
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion in administration system
Routes of administration	Intravenous drip use

Dosage and administration details:

10mg/kg

Number of subjects in period 1	Combination therapy
Started	42
1 year pf survival data collected	39
Completed	39
Not completed	3
Patient choice, patient choice	2
Protocol deviation	1

Baseline characteristics

Reporting groups

Reporting group title	Overall trial
-----------------------	---------------

Reporting group description:

Forty-two patients with no previous systemic therapy for SCLC were registered into this study between September 2011 and April 2014 at six sites in the United Kingdom

Reporting group values	Overall trial	Total	
Number of subjects	42	42	
Age categorical Units: Subjects			
Age continuous Units: years median full range (min-max)	63 44 to 84	-	
Gender categorical Units: Subjects			
Female	15	15	
Male	27	27	

End points

End points reporting groups

Reporting group title	Combination therapy
-----------------------	---------------------

Reporting group description: -

Primary: 1-year PFS according to RECIST v 1.0

End point title	1-year PFS according to RECIST v 1.0 ^[1]
-----------------	---

End point description:

95% Confidence Interval estimated using Wilson Interval

End point type	Primary
----------------	---------

End point timeframe:

The primary end point was 1-year PFS according to RECIST v 1.0. PFS was defined as the time from day 1 of the first cycle of chemotherapy to the date of progression or death from any cause.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Single arm trial

End point values	Combination therapy			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: percentage				
number (confidence interval 95%)	15.8 (7.4 to 30.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: irPFS at 1 year

End point title	irPFS at 1 year
-----------------	-----------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

1 year

End point values	Combination therapy			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: percentage				
number (confidence interval 95%)	12.6 (4.0 to 26.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Median Overall Survival

End point title	Median Overall Survival
End point description:	
End point type	Secondary
End point timeframe:	
Duration of Trial	

End point values	Combination therapy			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Months				
median (confidence interval 95%)	17.0 (7.9 to 24.3)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	Combination therapy
-----------------------	---------------------

Reporting group description: -

Serious adverse events	Combination therapy		
Total subjects affected by serious adverse events			
subjects affected / exposed	36 / 42 (85.71%)		
number of deaths (all causes)	8		
number of deaths resulting from adverse events	8		
Vascular disorders			
Thromboembolic event	Additional description: Thromboembolic event		
subjects affected / exposed	3 / 42 (7.14%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Fatigue	Additional description: Fatigue		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fever	Additional description: Fever		
subjects affected / exposed	2 / 42 (4.76%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Autoimmune disorder	Additional description: Autoimmune disorder		

subjects affected / exposed	2 / 42 (4.76%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Aspiration	Additional description: Aspiration		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Bronchopulmonary hemorrhage	Additional description: Bronchopulmonary hemorrhage		
subjects affected / exposed	2 / 42 (4.76%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pulmonary fibrosis	Additional description: Pulmonary fibrosis		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Dyspnoea	Additional description: Dyspnoea		
subjects affected / exposed	3 / 42 (7.14%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 1		
Investigations			
Alanine aminotransferase increased	Additional description: Alanine aminotransferase increased		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Blood antidiuretic hormone abnormal	Additional description: Blood antidiuretic hormone abnormal		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Other - Transaminitis	Additional description: Other - Transaminitis		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Neutrophil count decreased subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Neutrophil count decreased		
	3 / 42 (7.14%)		
	1 / 3		
	0 / 0		
Cardiac disorders Cardiac arrest subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cardiac arrest		
	1 / 42 (2.38%)		
	1 / 1		
	1 / 1		
Atrial fibrillation subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Atrial fibrillation		
	1 / 42 (2.38%)		
	0 / 1		
	0 / 0		
Nervous system disorders Other - Bells palsy subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Other - Bells palsy		
	1 / 42 (2.38%)		
	0 / 1		
	0 / 0		
Headache subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Headache		
	2 / 42 (4.76%)		
	2 / 3		
	0 / 0		
Seizure subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Seizure		
	2 / 42 (4.76%)		
	0 / 2		
	0 / 0		
Other - Immune related central neuropathy subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Other - Immune related central neuropathy		
	1 / 42 (2.38%)		
	1 / 1		
	1 / 1		
Dizziness subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Dizziness		
	1 / 42 (2.38%)		
	1 / 1		
	0 / 0		

Blood and lymphatic system disorders			
Febrile neutropenia	Additional description: Febrile neutropenia		
subjects affected / exposed	2 / 42 (4.76%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Pancytopenia	Additional description: Pancytopenia		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Anaemia	Additional description: Anaemia		
subjects affected / exposed	4 / 42 (9.52%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Colitis	Additional description: Colitis		
subjects affected / exposed	4 / 42 (9.52%)		
occurrences causally related to treatment / all	5 / 5		
deaths causally related to treatment / all	0 / 0		
Constipation	Additional description: Constipation		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diarrhoea	Additional description: Diarrhoea		
subjects affected / exposed	12 / 42 (28.57%)		
occurrences causally related to treatment / all	14 / 15		
deaths causally related to treatment / all	0 / 0		
Gastric haemorrhage	Additional description: Gastric haemorrhage		
subjects affected / exposed	2 / 42 (4.76%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	1 / 1		

Nausea	Additional description: Nausea		
	subjects affected / exposed	1 / 42 (2.38%)	
	occurrences causally related to treatment / all	0 / 1	
	deaths causally related to treatment / all	0 / 0	
Other - Ileitis	Additional description: Other - Ileitis		
	subjects affected / exposed	1 / 42 (2.38%)	
	occurrences causally related to treatment / all	1 / 1	
	deaths causally related to treatment / all	0 / 0	
Skin and subcutaneous tissue disorders	Additional description: Rash maculo-papular		
	Rash maculo-papular		
	subjects affected / exposed	1 / 42 (2.38%)	
	occurrences causally related to treatment / all	1 / 1	
Musculoskeletal and connective tissue disorders	Additional description: Generalised muscle weakness (Neurological)		
	Generalised muscle weakness (Neurological)		
	subjects affected / exposed	2 / 42 (4.76%)	
	occurrences causally related to treatment / all	0 / 2	
Other - Bilateral leg weakness	Additional description: Other - Bilateral leg weakness		
	subjects affected / exposed	1 / 42 (2.38%)	
	occurrences causally related to treatment / all	0 / 1	
	deaths causally related to treatment / all	0 / 0	
Pain	Additional description: Pain		
	subjects affected / exposed	1 / 42 (2.38%)	
	occurrences causally related to treatment / all	0 / 1	
	deaths causally related to treatment / all	0 / 0	
Generalised muscle weakness (Other)	Additional description: Generalised muscle weakness (Other)		
	subjects affected / exposed	1 / 42 (2.38%)	
	occurrences causally related to treatment / all	0 / 1	
	deaths causally related to treatment / all	0 / 0	
Infections and infestations	Additional description: Chest infection		
	Chest infection		

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lower Respiratory Tract Infection	Additional description: Lower Respiratory Tract Infection		
subjects affected / exposed	3 / 42 (7.14%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Sepsis	Additional description: Sepsis		
subjects affected / exposed	3 / 42 (7.14%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	1 / 1		
Other - Clostridium difficile	Additional description: Other - Clostridium difficile		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung infection	Additional description: Lung infection		
subjects affected / exposed	5 / 42 (11.90%)		
occurrences causally related to treatment / all	2 / 5		
deaths causally related to treatment / all	2 / 2		
Infection	Additional description: Infection		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory infection	Additional description: Upper respiratory infection		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypomagnesaemia	Additional description: Hypomagnesaemia		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia	Additional description: Hyperglycaemia		

subjects affected / exposed	2 / 42 (4.76%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Combination therapy		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	42 / 42 (100.00%)		
Vascular disorders			
Hypotension	Additional description: Hypotension		
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	4		
Hot flashes	Additional description: Hot flashes		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Thromboembolic event	Additional description: Thromboembolic event		
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Superficial thrombophlebitis	Additional description: Superficial thrombophlebitis		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
General disorders and administration site conditions			
Flu like symptoms	Additional description: Flu like symptoms		
subjects affected / exposed	7 / 42 (16.67%)		
occurrences (all)	7		
Fatigue	Additional description: Fatigue		
subjects affected / exposed	33 / 42 (78.57%)		
occurrences (all)	52		
Night sweats	Additional description: Night sweats		
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Oedema limbs	Additional description: Oedema limbs		
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Chills	Additional description: Chills		

subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Fever	Additional description: Fever		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Pain	Additional description: Pain		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Neck oedema	Additional description: Neck oedema		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 2		
Non-cardiac chest pain	Additional description: Non-cardiac chest pain		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Localised oedema	Additional description: Localised oedema		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Immune system disorders			
Autoimmune disorder	Additional description: Autoimmune disorder		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Allergic reaction	Additional description: Allergic reaction		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Respiratory, thoracic and mediastinal disorders			
Mucositis	Additional description: Mucositis		
subjects affected / exposed occurrences (all)	7 / 42 (16.67%) 9		
Bronchospasm	Additional description: Bronchospasm		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Sore throat	Additional description: Sore throat		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Dyspnoea	Additional description: Dyspnoea		

subjects affected / exposed occurrences (all)	16 / 42 (38.10%) 33		
Cough	Additional description: Cough		
subjects affected / exposed occurrences (all)	10 / 42 (23.81%) 12		
Lung infection	Additional description: Lung infection		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Upper respiratory infection	Additional description: Upper respiratory infection		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Pulmonary fibrosis	Additional description: Pulmonary fibrosis		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Aspiration	Additional description: Aspiration		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Hoarseness	Additional description: Hoarseness		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Productive cough	Additional description: Productive cough		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Bronchopulmonary hemorrhage	Additional description: Bronchopulmonary hemorrhage		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 4		
Psychiatric disorders	Additional description: Other - Increased anxiety/agitation		
Other - Increased anxiety/agitation subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Agitation	Additional description: Agitation		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Depression	Additional description: Depression		
subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 7		

Insomnia subjects affected / exposed occurrences (all)	Additional description: Insomnia	
	12 / 42 (28.57%)	13
Confusion subjects affected / exposed occurrences (all)	Additional description: Confusion	
	4 / 42 (9.52%)	7
Anxiety subjects affected / exposed occurrences (all)	Additional description: Anxiety	
	4 / 42 (9.52%)	5
Investigations		
Neutrophil count decreased subjects affected / exposed occurrences (all)	Additional description: Neutrophil count decreased	
	14 / 42 (33.33%)	25
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	Additional description: Activated partial thromboplastin time prolonged	
	1 / 42 (2.38%)	1
Blood bilirubin increased subjects affected / exposed occurrences (all)	Additional description: Blood bilirubin increased	
	5 / 42 (11.90%)	6
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	Additional description: Aspartate aminotransferase increased	
	4 / 42 (9.52%)	8
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	Additional description: Alanine aminotransferase increased	
	7 / 42 (16.67%)	9
Lymphocyte count decreased subjects affected / exposed occurrences (all)	Additional description: Lymphocyte count decreased	
	10 / 42 (23.81%)	22
Lymphocyte count increased subjects affected / exposed occurrences (all)	Additional description: Lymphocyte count increased	
	1 / 42 (2.38%)	1
INR increased subjects affected / exposed occurrences (all)	Additional description: INR increased	
	2 / 42 (4.76%)	2
Alkaline phosphatase increased	Additional description: Alkaline phosphatase increased	

subjects affected / exposed occurrences (all)	10 / 42 (23.81%) 24		
Lymphopenia	Additional description: Lymphopenia		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Other - Transaminitis	Additional description: Other - Transaminitis		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Elevated lactate dehydrogenase	Additional description: Elevated lactate dehydrogenase		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Platelet count decreased	Additional description: Platelet count decreased		
subjects affected / exposed occurrences (all)	7 / 42 (16.67%) 8		
White blood cell decreased	Additional description: White blood cell decreased		
subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 11		
Blood antidiuretic hormone abnormal	Additional description: Blood antidiuretic hormone abnormal		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Creatinine increased	Additional description: Creatinine increased		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 5		
GGT increased	Additional description: GGT increased		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3		
Weight loss	Additional description: Weight loss		
subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 7		
Cardiac disorders			
Cardiac arrest	Additional description: Cardiac arrest		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Chest pain - cardiac	Additional description: Chest pain - cardiac		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		

Atrial fibrillation subjects affected / exposed occurrences (all)	Additional description: Atrial fibrillation 1 / 42 (2.38%) 1		
Nervous system disorders			
Cognitive disturbance subjects affected / exposed occurrences (all)	Additional description: Cognitive disturbance 1 / 42 (2.38%) 1		
Peripheral neuropathy subjects affected / exposed occurrences (all)	Additional description: Peripheral neuropathy 2 / 42 (4.76%) 2		
Light headed subjects affected / exposed occurrences (all)	Additional description: Light headed 1 / 42 (2.38%) 1		
Seizure subjects affected / exposed occurrences (all)	Additional description: Seizure 2 / 42 (4.76%) 2		
Other - Neuropathy subjects affected / exposed occurrences (all)	Additional description: Other - Neuropathy 3 / 42 (7.14%) 3		
Concentration impairment subjects affected / exposed occurrences (all)	Additional description: Concentration impairment 2 / 42 (4.76%) 2		
Dizziness subjects affected / exposed occurrences (all)	Additional description: Dizziness 8 / 42 (19.05%) 10		
Dysarthria subjects affected / exposed occurrences (all)	Additional description: Dysarthria 3 / 42 (7.14%) 3		
Paraesthesia subjects affected / exposed occurrences (all)	Additional description: Paraesthesia 4 / 42 (9.52%) 5		
Memory impairment subjects affected / exposed occurrences (all)	Additional description: Memory impairment 1 / 42 (2.38%) 1		
Facial nerve disorder	Additional description: Facial nerve disorder		

subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Dysgeusia	Additional description: Dysgeusia		
subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 6		
Lethargy	Additional description: Lethargy		
subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 4		
Tremour	Additional description: Tremour		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Somnolence	Additional description: Somnolence		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 2		
Peripheral sensory neuropathy	Additional description: Peripheral sensory neuropathy		
subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 4		
Amnesia	Additional description: Amnesia		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Facial muscle weakness	Additional description: Facial muscle weakness		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3		
Other - Nervous system disorder	Additional description: Other - Nervous system disorder		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Headache	Additional description: Headache		
subjects affected / exposed occurrences (all)	13 / 42 (30.95%) 18		
Movements involuntary	Additional description: Movements involuntary		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3		
Other - Focal seizures	Additional description: Other - Focal seizures		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Blood and lymphatic system disorders			

Other - Raised platelets subjects affected / exposed occurrences (all)	Additional description: Other - Raised platelets		
	1 / 42 (2.38%) 1		
Febrile neutropenia subjects affected / exposed occurrences (all)	Additional description: Febrile neutropenia		
	2 / 42 (4.76%) 2		
Anaemia subjects affected / exposed occurrences (all)	Additional description: Anaemia		
	21 / 42 (50.00%) 58		
Thrombocytopenia subjects affected / exposed occurrences (all)	Additional description: Thrombocytopenia		
	5 / 42 (11.90%) 9		
Pancytopenia subjects affected / exposed occurrences (all)	Additional description: Pancytopenia		
	2 / 42 (4.76%) 2		
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	Additional description: Ear pain		
	2 / 42 (4.76%) 2		
Hearing impaired subjects affected / exposed occurrences (all)	Additional description: Hearing impaired		
	1 / 42 (2.38%) 1		
Other - Inner ear popping sensation subjects affected / exposed occurrences (all)	Additional description: Other - Inner ear popping sensation		
	1 / 42 (2.38%) 1		
Eye disorders			
Other - Right subconjunctival haemorrhage subjects affected / exposed occurrences (all)	Additional description: Other - Right subconjunctival haemorrhage		
	1 / 42 (2.38%) 1		
Eye pain subjects affected / exposed occurrences (all)	Additional description: Eye pain		
	1 / 42 (2.38%) 1		
Watering eyes subjects affected / exposed occurrences (all)	Additional description: Watering eyes		
	2 / 42 (4.76%) 2		
Gastrointestinal disorders			

Oesophageal pain subjects affected / exposed occurrences (all)	Additional description: Oesophageal pain 1 / 42 (2.38%) 1		
Diarrhoea subjects affected / exposed occurrences (all)	Additional description: Diarrhoea 28 / 42 (66.67%) 60		
Mucositis oral subjects affected / exposed occurrences (all)	Additional description: Mucositis oral 2 / 42 (4.76%) 2		
Nausea subjects affected / exposed occurrences (all)	Additional description: Nausea 24 / 42 (57.14%) 39		
Other - Soreness & dermal adema to buccal mucose and vulva subjects affected / exposed occurrences (all)	Additional description: Other - Soreness & dermal adema to buccal mucose and vulva 1 / 42 (2.38%) 1		
Vomiting subjects affected / exposed occurrences (all)	Additional description: Vomiting 17 / 42 (40.48%) 19		
Other - Ileitis subjects affected / exposed occurrences (all)	Additional description: Other - Ileitis 1 / 42 (2.38%) 1		
Rectal hemorrhage subjects affected / exposed occurrences (all)	Additional description: Rectal hemorrhage 1 / 42 (2.38%) 2		
Stomach pain subjects affected / exposed occurrences (all)	Additional description: Stomach pain 2 / 42 (4.76%) 2		
Flatulence subjects affected / exposed occurrences (all)	Additional description: Flatulence 1 / 42 (2.38%) 1		
Dysgeusia subjects affected / exposed occurrences (all)	Additional description: Dysgeusia 5 / 42 (11.90%) 5		
Dysphagia	Additional description: Dysphagia		

subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 5		
Dyspepsia	Additional description: Dyspepsia		
subjects affected / exposed occurrences (all)	9 / 42 (21.43%) 10		
Abdominal pain	Additional description: Abdominal pain		
subjects affected / exposed occurrences (all)	11 / 42 (26.19%) 18		
Constipation	Additional description: Constipation		
subjects affected / exposed occurrences (all)	16 / 42 (38.10%) 18		
Gastric haemorrhage	Additional description: Gastric haemorrhage		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Anorexia	Additional description: Anorexia		
subjects affected / exposed occurrences (all)	7 / 42 (16.67%) 10		
Pain	Additional description: Pain		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Haemorrhoids	Additional description: Haemorrhoids		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Sore mouth	Additional description: Sore mouth		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Colitis	Additional description: Colitis		
subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 6		
Dry mouth	Additional description: Dry mouth		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 4		
Dental caries	Additional description: Dental caries		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Bloating	Additional description: Bloating		

subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Mucositis	Additional description: Mucositis		
subjects affected / exposed	6 / 42 (14.29%)		
occurrences (all)	7		
Skin and subcutaneous tissue disorders			
Other - Facial rash + upper shoulder rash	Additional description: Other - Facial rash + upper shoulder rash		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Other - Facial rash	Additional description: Other - Facial rash		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Pruritus	Additional description: Pruritus		
subjects affected / exposed	11 / 42 (26.19%)		
occurrences (all)	15		
Dry skin	Additional description: Dry skin		
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	6		
Urticaria	Additional description: Urticaria		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Other - Facial redness puffiness	Additional description: Other - Facial redness puffiness		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Scalp pain	Additional description: Scalp pain		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Other - Facial swelling	Additional description: Other - Facial swelling		
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Alopecia	Additional description: Alopecia		
subjects affected / exposed	20 / 42 (47.62%)		
occurrences (all)	23		
Palmar-plantar erythrodysesthesia syndrome	Additional description: Palmar-plantar erythrodysesthesia syndrome		

subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Rash	Additional description: Rash		
subjects affected / exposed occurrences (all)	21 / 42 (50.00%) 31		
Rash maculo-papular	Additional description: Rash maculo-papular		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Renal and urinary disorders			
Urinary retention	Additional description: Urinary retention		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Dysuria	Additional description: Dysuria		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Endocrine disorders			
Hypothyroidism	Additional description: Hypothyroidism		
subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 7		
Hyperthyroidism	Additional description: Hyperthyroidism		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Other - thyroiditis	Additional description: Other - thyroiditis		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 2		
Cushingoid	Additional description: Cushingoid		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Musculoskeletal and connective tissue disorders			
Neck pain	Additional description: Neck pain		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Generalised muscle weakness (Other)	Additional description: Generalised muscle weakness (Other)		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Arthralgia	Additional description: Arthralgia		

subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Myalgia	Additional description: Myalgia		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Other - Ache in right arm	Additional description: Other - Ache in right arm		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Generalised muscle weakness (Neurological)	Additional description: Generalised muscle weakness (Neurological)		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Pain	Additional description: Pain		
subjects affected / exposed occurrences (all)	15 / 42 (35.71%) 20		
Bone pain	Additional description: Bone pain		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Back pain	Additional description: Back pain		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Other - Bilateral leg weakness	Additional description: Other - Bilateral leg weakness		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Infections and infestations			
Upper respiratory infection	Additional description: Upper respiratory infection		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3		
Eye infection	Additional description: Eye infection		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Sepsis	Additional description: Sepsis		
subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 4		
Oral thrush	Additional description: Oral thrush		

subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 6		
Infection	Additional description: Infection		
subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 6		
Skin infection	Additional description: Skin infection		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Upper respiratory tract infection	Additional description: Upper respiratory tract infection		
subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 4		
Lip infection	Additional description: Lip infection		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Other - Viral infection	Additional description: Other - Viral infection		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Urinary tract infection	Additional description: Urinary tract infection		
subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 6		
Ear infection	Additional description: Ear infection		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Other - Clostridium difficile	Additional description: Other - Clostridium difficile		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Anorectal infection	Additional description: Anorectal infection		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Lung infection	Additional description: Lung infection		
subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 6		
Lower Respiratory Tract Infection	Additional description: Lower Respiratory Tract Infection		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Chest infection	Additional description: Chest infection		

subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 5		
Metabolism and nutrition disorders			
Hypercalcaemia	Additional description: Hypercalcaemia		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 2		
Anorexia	Additional description: Anorexia		
subjects affected / exposed occurrences (all)	11 / 42 (26.19%) 14		
Hypermagnesemia	Additional description: Hypermagnesemia		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Hypoalbuminaemia	Additional description: Hypoalbuminaemia		
subjects affected / exposed occurrences (all)	10 / 42 (23.81%) 32		
Hypocalcaemia	Additional description: Hypocalcaemia		
subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 6		
Dehydration	Additional description: Dehydration		
subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Hypomagnesaemia	Additional description: Hypomagnesaemia		
subjects affected / exposed occurrences (all)	10 / 42 (23.81%) 24		
Hyperglycaemia	Additional description: Hyperglycaemia		
subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Hypokalaemia	Additional description: Hypokalaemia		
subjects affected / exposed occurrences (all)	9 / 42 (21.43%) 17		
Hyponatraemia	Additional description: Hyponatraemia		
subjects affected / exposed occurrences (all)	8 / 42 (19.05%) 27		
Hypophosphataemia	Additional description: Hypophosphataemia		
subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported